

# Eitan Amir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4170361/publications.pdf>

Version: 2024-02-01

341  
papers

16,148  
citations

26567

56  
h-index

20900

115  
g-index

344  
all docs

344  
docs citations

344  
times ranked

23954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Resource stratified guidelines for cancer: Are they all the same? Interguideline concordance for systemic treatment recommendations. <i>International Journal of Cancer</i> , 2022, 150, 91-99.	2.3	4
2	Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110726.	1.4	7
3	Prioritising access to cancer drugs. <i>Lancet Oncology</i> , The, 2022, 23, e1.	5.1	0
4	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	0
5	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, , 1.	1.6	2
6	A Combined Echocardiography Approach for the Diagnosis of Cancer Therapy-Related Cardiac Dysfunction in Women With Early-Stage Breast Cancer. <i>JAMA Cardiology</i> , 2022, 7, 330.	3.0	16
7	Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 847.	1.0	6
8	Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 43.	2.3	1
9	The Impact of Cognitive Impairment on Treatment Toxicity, Treatment Completion, and Survival among Older Adults Receiving Chemotherapy: A Systematic Review. <i>Cancers</i> , 2022, 14, 1582.	1.7	5
10	Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 80, 436-448.e1.	2.1	21
11	A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. <i>Scientific Reports</i> , 2022, 12, 6352.	1.6	3
12	Clinical benefit of cancer drugs approved in Switzerland 2010-2019. <i>PLoS ONE</i> , 2022, 17, e0268545.	1.1	2
13	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136.	1.6	13
14	Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 962-974.	2.3	50
15	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1465-1475.	3.0	50
16	Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours. <i>Cancer Treatment Reviews</i> , 2021, 94, 102167.	3.4	8
17	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 5787-5795.	1.0	6
18	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3369-3379.	1.2	21

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 415-417.	5.1	3
20	Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. <i>Scientific Reports</i> , 2021, 11, 10843.	1.6	1
21	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. <i>European Journal of Cancer</i> , 2021, 149, 117-127.	1.3	7
22	Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. <i>JCO Global Oncology</i> , 2021, 7, 1074-1083.	0.8	3
23	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 77.	2.3	16
24	Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. <i>Cancer Medicine</i> , 2021, 10, 5405-5414.	1.3	2
25	Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study. <i>Circulation: Heart Failure</i> , 2021, 14, e008110.	1.6	8
26	Patient and provider determinants of breast cancer screening among Ontario women aged 40-49: a population-based retrospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 631-640.	1.1	4
27	Adjuvant Zoledronate Therapy for Women With Breast Cancer—Effective Treatment or Fool's Gold?. <i>JAMA Oncology</i> , 2021, 7, 1121.	3.4	2
28	Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i> -Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, e212140.	3.4	12
29	Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102283.	3.4	13
30	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102293.	3.4	3
31	Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. <i>Journal of Cancer</i> , 2021, 12, 4372-4378.	1.2	9
32	Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score-Matched Cohort Study. <i>Journal of the American Heart Association</i> , 2021, 10, e018393.	1.6	47
33	Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 117-125.	2.3	4
34	Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1433-1440.	2.3	2
35	Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. <i>Cancer Treatment Reviews</i> , 2021, 101, 102310.	3.4	2
36	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 101, 102299.	3.4	3

#	ARTICLE	IF	CITATIONS
37	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.	0.9	10
38	Feasibility of a Remotely Delivered Strength and Balance Training Program for Older Adults with Cancer. <i>Current Oncology</i> , 2021, 28, 4408-4419.	0.9	2
39	Clinical, Echocardiographic, and Biomarker Associations With Impaired Cardiorespiratory Fitness Early After HER2-Targeted Breast Cancer Therapy. <i>JACC: CardioOncology</i> , 2021, 3, 678-691.	1.7	10
40	Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals. <i>European Journal of Internal Medicine</i> , 2020, 71, 45-49.	1.0	5
41	Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 951-962.	2.3	34
42	Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). <i>Cancer Medicine</i> , 2020, 9, 116-124.	1.3	17
43	Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 90, 102086.	3.4	29
44	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. <i>Cancer</i> , 2020, 126, 4390-4399.	2.0	19
45	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	3.4	61
46	Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020, 9, 7888-7895.	1.3	5
47	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	3.4	4
48	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2020, 21, 61-68.	0.2	2
49	Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091529.	1.4	17
50	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 676-685.	0.4	9
51	Impact of Cancer Therapy-Related Cardiac Dysfunction on Risk of Heart Failure in Pregnancy. <i>JACC: CardioOncology</i> , 2020, 2, 153-162.	1.7	17
52	The Yield of Routine Cardiac Imaging in Breast Cancer Patients Receiving Trastuzumab-Based Treatment: A Retrospective Cohort Study. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1658-1666.	0.8	4
53	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020, 6, 22.	2.3	7
54	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 259-266.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. <i>Heart</i> , 2020, 106, 817-823.	1.2	50
56	Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. <i>Scientific Reports</i> , 2020, 10, 4091.	1.6	7
57	Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol. <i>BMJ Open</i> , 2020, 10, e035648.	0.8	4
58	Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. , 2020, 8, e000467.		106
59	Integrin $\alpha 6$ Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 143-151.	1.6	6
60	Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer. <i>American Journal of Cardiology</i> , 2020, 125, 1270-1275.	0.7	14
61	Informative censoring â€” a neglected cause of bias in oncology trials. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 327-328.	12.5	43
62	Modified Routine Cardiac Imaging Surveillance of Adult Cancer Patients and Survivors During the COVID-19 Pandemic. <i>JACC: CardioOncology</i> , 2020, 2, 345-349.	1.7	14
63	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. <i>Breast Cancer Research</i> , 2020, 22, 15.	2.2	53
64	Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial. <i>Journal of Geriatric Oncology</i> , 2019, 10, 169-174.	0.5	10
65	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , 2019, 24, 1439-1445.	1.9	40
66	The Effect of Exercise on Quality of Life, Fatigue, Physical Function, and Safety in Advanced Solid Tumor Cancers: A Meta-analysis of Randomized Control Trials. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 899-908.e7.	0.6	40
67	Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review. <i>European Journal of Cancer</i> , 2019, 118, 189.	1.3	0
68	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>Oncolimmunology</i> , 2019, 8, e1629780.	2.1	34
69	The Voices of Young Women with Breast Cancer: Providing Support and Information for Improved Fertility Preservation Discussions. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 547-553.	0.7	7
70	Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines. <i>Cancer</i> , 2019, 125, 4069-4075.	2.0	30
71	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz033.	1.4	20
72	A critique of the fragility index. <i>Lancet Oncology</i> , The, 2019, 20, e552.	5.1	12

#	ARTICLE	IF	CITATIONS
73	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	1.3	38
74	Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. <i>Journal of Surgical Oncology</i> , 2019, 120, 1055-1055.	0.8	0
75	Assisting with Decision-Making: How Standardized Information Impacts Breast Cancer Patient Decisions Regarding Fertility Trade-Offs and Chemotherapy. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 660-667.	0.7	3
76	Association Between Data Sources and US Food and Drug Administration Drug Safety Communications. <i>JAMA Internal Medicine</i> , 2019, 179, 1590.	2.6	18
77	Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation. <i>JAMA Network Open</i> , 2019, 2, e1911838.	2.8	18
78	Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. <i>European Heart Journal</i> , 2019, 40, 3913-3920.	1.0	60
79	Endpoint selection in HER2-positive early breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, 315-316.	5.1	0
80	The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 854-862.	3.0	49
81	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 77, 11-19.	3.4	14
82	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 374-387.	1.8	19
83	The Impact of Big Data Research on Practice, Policy, and Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e167-e175.	1.8	18
84	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 76, 51-56.	3.4	36
85	Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial. <i>BMJ Open</i> , 2019, 9, e024485.	0.8	23
86	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. <i>PLoS ONE</i> , 2019, 14, e0209134.	1.1	16
87	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 932-940.	0.8	11
88	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019, 8, 1584-1593.	1.3	18
89	Role of Bisphosphonates in Breast Cancer Therapy. <i>Current Treatment Options in Oncology</i> , 2019, 20, 26.	1.3	43
90	Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 531-545.	1.1	42

#	ARTICLE	IF	CITATIONS
91	Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 448-455.	2.6	10
92	Undisclosed Financial Conflicts of Interest of Authors of Clinical Drug Trials Published in Influential Medical Journals: A Cohort Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2272-2276.	1.4	7
93	Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV. <i>JAMA Network Open</i> , 2019, 2, e1914816.	2.8	11
94	Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 727-736.	3.0	84
95	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. <i>Mayo Clinic Proceedings</i> , 2019, 94, 74-83.	1.4	10
96	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. <i>JAMA Oncology</i> , 2019, 5, 107.	3.4	2
97	Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. <i>Canadian Journal of Cardiology</i> , 2019, 35, 153-159.	0.8	49
98	Competing risks of extended adjuvant aromatase inhibitors. <i>Lancet Oncology</i> , The, 2019, 20, 8-9.	5.1	3
99	A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 875-883.	0.5	13
100	Abstract P4-14-03: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer. , 2019, , .		1
101	Evaluating the value of checkpoint inhibitor therapy using the ASCO and ESMO frameworks.. <i>Journal of Clinical Oncology</i> , 2019, 37, 17-17.	0.8	0
102	FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 411-411.	0.8	0
103	Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review.. <i>Journal of Clinical Oncology</i> , 2019, 37, 511-511.	0.8	0
104	EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting. <i>British Journal of Cancer</i> , 2018, 118, 617-618.	2.9	2
105	Functional transcriptomic annotation and protein-protein interaction analysis identify <sc>EZH</sc>2 and <sc>UBE</sc>2C as key upregulated proteins in ovarian cancer. <i>Cancer Medicine</i> , 2018, 7, 1896-1907.	1.3	14
106	Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2018, 30, 215-224.	0.6	28
107	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 486-492.	3.0	70
108	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 413-425.	1.1	14

#	ARTICLE	IF	CITATIONS
109	Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) – A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 63, 71-78.	3.4	16
110	Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study. <i>European Journal of Cancer</i> , 2018, 94, 199-205.	1.3	21
111	A randomized phase II trial of geriatric assessment and management for older cancer patients. <i>Supportive Care in Cancer</i> , 2018, 26, 109-117.	1.0	32
112	Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 62, 1-8.	3.4	69
113	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e193-e199.	0.9	13
114	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 31-39.	3.0	129
115	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	1.1	27
116	Reporting of Randomized Trials in Common Cancers in the Lay Media. <i>Oncology</i> , 2018, 94, 65-71.	0.9	1
117	Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2980-2987.	0.8	37
118	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	0.8	27
119	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S995-S998.	0.6	1
120	Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?. <i>Oncotarget</i> , 2018, 9, 30942-30943.	0.8	1
121	Response. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1145-1145.	3.0	0
122	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials. <i>JAMA Oncology</i> , 2018, 4, 1610.	3.4	27
123	Refining Early Antitumoral Drug Development. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 922-925.	4.0	17
124	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis. <i>European Journal of Cancer</i> , 2018, 105, 1-9.	1.3	69
125	Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 71, 68-75.	3.4	9
126	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. <i>Oncotarget</i> , 2018, 9, 31915-31919.	0.8	14



#	ARTICLE	IF	CITATIONS
127	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 725-732.	1.1	9
128	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 138-143.	3.4	9
129	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
130	Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 69, 1-10.	3.4	44
131	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky028.	1.4	10
132	Importance of Considering Competing Risks in Time-to-Event Analyses. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004580.	0.9	80
133	Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1094-1094.	0.8	2
134	Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12501-e12501.	0.8	2
135	Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer. <i>Oncotarget</i> , 2018, 9, 15061-15067.	0.8	2
136	Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18717-e18717.	0.8	0
137	Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6619-6619.	0.8	0
138	Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6588-6588.	0.8	0
139	Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 145, 584-594.	0.6	85
140	Association of the Timing of Pregnancy With Survival in Women With Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 659.	3.4	82
141	Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer. <i>Current Oncology Reports</i> , 2017, 19, 15.	1.8	1
142	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 337-343.	1.6	4
143	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. <i>Cancer Treatment Reviews</i> , 2017, 56, 1-7.	3.4	42
144	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017, 123, 1409-1415.	2.0	9

#	ARTICLE	IF	CITATIONS
145	Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. <i>Experimental and Molecular Pathology</i> , 2017, 102, 455-474.	0.9	17
146	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2017, 77, 40-47.	1.3	52
147	Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. <i>Annals of Oncology</i> , 2017, 28, 628-633.	0.6	43
148	Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 53, 120-127.	3.4	178
149	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 60, 53-59.	3.4	21
150	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 59, 46-53.	3.4	2
151	Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	130
152	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. <i>Scientific Reports</i> , 2017, 7, 17530.	1.6	53
153	Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 147, 158-166.	0.6	71
154	Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. <i>Supportive Care in Cancer</i> , 2017, 25, 879-886.	1.0	39
155	A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. <i>JAMA Cardiology</i> , 2017, 2, 88.	3.0	232
156	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 909.	1.8	21
157	Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians. <i>Molecular and Clinical Oncology</i> , 2017, 8, 153-158.	0.4	10
158	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research</i> , 2017, 19, 2.	2.2	457
159	Impact of the Pan-Canadian Oncology Drug Review on Provincial Concordance with Respect to Cancer Drug Funding Decisions and Time to Funding. <i>Current Oncology</i> , 2017, 24, 295-301.	0.9	8
160	Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?. <i>Journal of Clinical Oncology</i> , 2017, 35, 820-825.	0.8	5
161	Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 549-549.	0.8	1
162	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , 2017, 12, e0175128.	1.1	28

#	ARTICLE	IF	CITATIONS
163	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , 2017, 8, 21733-21740.	0.8	18
164	General Overview and Treatment Recommendations for Young Women with Breast Cancer. <i>Revista De Investigacion Clinica</i> , 2017, 69, 77-93.	0.2	11
165	Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (RO) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4114-4114.	0.8	0
166	Efficacy, safety, tolerability and price of newly approved drugs in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18336-e18336.	0.8	1
167	Hyperglycemia and survival in solid tumors: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18158-e18158.	0.8	0
168	Update in treatment of early breast cancer in post-menopausal women. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 243-252.	1.2	0
169	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology, The</i> , 2016, 17, e560-e567.	5.1	74
170	Bias in reporting of randomised clinical trials in oncology. <i>European Journal of Cancer</i> , 2016, 61, 29-35.	1.3	42
171	Does a dedicated program for young breast cancer patients affect the likelihood of fertility preservation discussion and referral?. <i>Breast</i> , 2016, 27, 22-26.	0.9	29
172	Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.	1.0	9
173	Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2239-2246.	0.8	125
174	Under-reporting of harm in clinical trials. <i>Lancet Oncology, The</i> , 2016, 17, e209-e219.	5.1	76
175	Reply to L.A. Renfro et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3950-3950.	0.8	0
176	The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. <i>European Journal of Cancer</i> , 2016, 68, 11-21.	1.3	65
177	Honorary and ghost authorship in reports of randomised clinical trials in oncology. <i>European Journal of Cancer</i> , 2016, 66, 1-8.	1.3	23
178	A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support. <i>American Journal of Cardiology</i> , 2016, 118, 1539-1544.	0.7	10
179	Toward Value-Based Pricing to Boost Cancer Research and Innovation. <i>Cancer Research</i> , 2016, 76, 3127-3129.	0.4	15
180	The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 307-313.	1.6	6

#	ARTICLE	IF	CITATIONS
181	Rethinking end-points for bone-targeted therapy in advanced cancer. <i>European Journal of Cancer</i> , 2016, 63, 105-109.	1.3	6
182	Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies. <i>Cancer Treatment Reviews</i> , 2016, 43, 67-73.	3.4	28
183	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. <i>Clinical Oncology</i> , 2016, 28, 283-291.	0.6	3
184	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 1-8.	1.1	10
185	Prevention, Detection, and Management of Chemotherapy-Related Cardiac Dysfunction. <i>Canadian Journal of Cardiology</i> , 2016, 32, 891-899.	0.8	15
186	Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2016, 45, 1-6.	3.4	21
187	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	0.9	133
188	Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration. <i>JAMA Oncology</i> , 2016, 2, 744.	3.4	17
189	Cardiac Outcomes in Survivors of Pediatric and Adult Cancers. <i>Canadian Journal of Cardiology</i> , 2016, 32, 871-880.	0.8	33
190	Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting. <i>Journal of Clinical Oncology</i> , 2016, 34, 1469-1475.	0.8	36
191	Circulating DNA and Survival in Solid Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 399-406.	1.1	30
192	Abstract P2-08-05: Association between the neutrophil-to-lymphocyte ratio (NLR) and the 21-gene recurrence score. , 2016, , .		1
193	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. <i>PLoS ONE</i> , 2016, 11, e0154789.	1.1	31
194	<i>In silico</i> analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. <i>Oncotarget</i> , 2016, 7, 22865-22872.	0.8	21
195	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. <i>Oncotarget</i> , 2016, 7, 45042-45051.	0.8	21
196	Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16058-e16058.	0.8	0
197	The impact of multimodality therapy in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program Experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11051-11051.	0.8	0
198	A feasibility trial of geriatric assessment and integrated care plan for older cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10054-10054.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Outcomes of single versus double hormone receptor positive breast cancer.. Journal of Clinical Oncology, 2016, 34, 569-569.	0.8	1
200	Treatment-related side effects as predictors of efficacy of check-point inhibitors (CPIs).. Journal of Clinical Oncology, 2016, 34, 3062-3062.	0.8	5
201	Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. Journal of Bone Oncology, 2015, 4, 54-58.	1.0	17
202	Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel. Radiology and Oncology, 2015, 49, 402-408.	0.6	7
203	1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer. European Journal of Cancer, 2015, 51, S176-S177.	1.3	1
204	Birth-Weight, Pregnancy Term, Pre-Natal and Natal Complications Related to Child's Dental Anomalies. Journal of Clinical Pediatric Dentistry, 2015, 39, 371-376.	0.5	15
205	Outcome of Adjuvant Therapy in Biliary Tract Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 382-387.	0.6	36
206	Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. PLoS ONE, 2015, 10, e0122735.	1.1	14
207	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS ONE, 2015, 10, e0132449.	1.1	41
208	Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy. Journal of Oncology, 2015, 2015, 1-10.	0.6	43
209	Aromatase inhibitors for prevention of breast cancer in postmenopausal women. Menopause, 2015, 22, 342-350.	0.8	8
210	Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients. Supportive Care in Cancer, 2015, 23, 3269-3275.	1.0	17
211	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. Journal of Clinical Oncology, 2015, 33, 1298-1299.	0.8	32
212	Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of Clinical Pathology, 2015, 68, 839-843.	1.0	6
213	Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. Journal of Clinical Oncology, 2015, 33, 100-106.	0.8	47
214	Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of Oncology, 2015, 26, 743-749.	0.6	119
215	Pathological complete response in breast cancer. Lancet, The, 2015, 385, 113.	6.3	1
216	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. Journal of Clinical Oncology, 2015, 33, 582-587.	0.8	50

#	ARTICLE	IF	CITATIONS
217	The use of myocardial strain and newer echocardiography imaging techniques in cancer patients. <i>Future Oncology</i> , 2015, 11, 2035-2041.	1.1	3
218	One step forward, two steps back: The story of everolimus in advanced breast cancer. <i>Breast</i> , 2015, 24, 529-531.	0.9	4
219	Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor-Positive Early Breast Cancer in Canada. <i>Current Oncology</i> , 2015, 22, 84-96.	0.9	14
220	Influence of censoring on conclusions of trials for women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 721-724.	1.3	16
221	Efficacy-effectiveness gap as an obstacle to translating clinical trials to clinical practice. <i>European Journal of Cancer</i> , 2015, 51, 905-906.	1.3	5
222	Failures in Phase III: Causes and Consequences. <i>Clinical Cancer Research</i> , 2015, 21, 4552-4560.	3.2	70
223	Response. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv244.	3.0	1
224	PK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015, 22, 577-589.	7.2	430
225	Systemic Therapy for Non-clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2015, 67, 740-749.	0.9	166
226	Forty years of randomized trials in advanced/metastatic soft tissue sarcoma (STS): Endpoint selection, surrogacy and quality of reporting.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10513-10513.	0.8	1
227	Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT).. <i>Journal of Clinical Oncology</i> , 2015, 33, e11588-e11588.	0.8	2
228	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
229	The price of survival: Breast cancer patient preferences about fertility.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9561-9561.	0.8	0
230	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e95219.	1.1	140
231	Raising Concern About the American Society of Clinical Oncology Conflict of Interest Policy Amendment. <i>Journal of Clinical Oncology</i> , 2014, 32, 3197-3197.	0.8	2
232	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-lymphocyte ratio. <i>Cancer</i> , 2014, 120, 3346-3352.	2.0	128
233	Association of Aromatase Inhibitors With Coronary Heart Disease in Women With Early Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 99-104.	0.6	20
234	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. <i>SpringerPlus</i> , 2014, 3, 577.	1.2	18

#	ARTICLE	IF	CITATIONS
235	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 295-307.	2.7	5
236	Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 760-762.	0.6	7
237	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1048-1055.	3.4	34
238	Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3634-3642.	0.8	64
239	Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt319-djt319.	3.0	279
240	Human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis. <i>Journal of Clinical Virology</i> , 2014, 61, 220-229.	1.6	4
241	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 615-624.	1.1	25
242	Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 267-279.	1.1	10
243	Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1204-1212.	1.1	519
244	Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. <i>European Journal of Cancer</i> , 2014, 50, 1581-1589.	1.3	119
245	Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. <i>Journal of Geriatric Oncology</i> , 2014, 5, 119-126.	0.5	68
246	Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting. <i>Journal of Bone Oncology</i> , 2014, 3, 1-4.	1.0	5
247	Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 235-244.	1.1	73
248	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju124.	3.0	2,202
249	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 70-70.	0.8	3
250	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e88238.	1.1	51
251	Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE). <i>Journal of Clinical Oncology</i> , 2014, 32, 5047-5047.	0.8	0
252	Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 567-567.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Benefit and Harms of New Anti-Cancer Drugs. <i>Current Oncology Reports</i> , 2013, 15, 270-275.	1.8	30
254	Does estrogen play a role in response to adjuvant bone-targeted therapies?. <i>Journal of Bone Oncology</i> , 2013, 2, 167-173.	1.0	6
255	Fulvestrant for advanced breast cancer: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2013, 39, 753-758.	3.4	29
256	Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267.	0.8	83
257	Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 603-606.	1.1	86
258	Clinical trial design in biosimilar drug development. <i>Investigational New Drugs</i> , 2013, 31, 479-487.	1.2	41
259	Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 154-167.	2.0	113
260	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. <i>Journal of Bone Oncology</i> , 2013, 2, 154-157.	1.0	15
261	The evolving landscape of protein kinases in breast cancer: Clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 68-76.	3.4	20
262	Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. <i>Annals of Oncology</i> , 2013, 24, 1238-1244.	0.6	104
263	Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing. <i>Journal of Clinical Oncology</i> , 2013, 31, 1252-1253.	0.8	2
264	Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 436-442.	0.6	33
265	Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. <i>Annals of Oncology</i> , 2013, 24, 2972-2977.	0.6	117
266	Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. <i>Clinical Cancer Research</i> , 2013, 19, 4931-4940.	3.2	21
267	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 266-273.	3.0	168
268	Treatment Recommendations for the Use of Bone-Targeted Agents in 2011 Report from the 6th Annual Bone and the Oncologist New Updates Meeting. <i>Current Oncology</i> , 2012, 19, 364-370.	0.9	4
269	Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. <i>Annals of Oncology</i> , 2012, 23, 2977-2982.	0.6	15
270	<i>p53 Arg72Pro</i> Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Cancer Research</i> , 2012, 18, 6407-6415.	3.2	46



#	ARTICLE	IF	CITATIONS
271	Benefits and Harms of Detecting Clinically Occult Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 1542-1547.	3.0	13
272	Mandibular Block or Maxillary Infiltration. Journal of Clinical Pediatric Dentistry, 2012, 36, 245-250.	0.5	6
273	Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer. Journal of Clinical Oncology, 2012, 30, 587-592.	0.8	377
274	How valid are claims for synergy in published clinical studies?. Annals of Oncology, 2012, 23, 2161-2166.	0.6	33
275	Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 1934-1940.	0.8	602
276	ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Research, 2012, 14, R149.	2.2	40
277	Management of small HER2 overexpressing tumours. Breast Cancer Research and Treatment, 2012, 136, 289-293.	1.1	14
278	Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?. European Journal of Cancer, 2012, 48, 385-388.	1.3	84
279	Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2012, 18, 4526-4537.	3.2	48
280	Dual Blockade of HER2 " Twice as Good or Twice as Toxic?. Clinical Oncology, 2012, 24, 593-603.	0.6	5
281	Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews, 2012, 38, 708-714.	3.4	153
282	The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. Journal of Clinical Oncology, 2012, 30, 3012-3019.	0.8	152
283	Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes. Molecular and Cellular Biology, 2012, 32, 2979-2991.	1.1	89
284	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Research and Treatment, 2012, 133, 1077-1088.	1.1	51
285	Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review. Gynecologic Oncology, 2012, 124, 354-365.	0.6	32
286	Abstract P3-13-05: Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: A pragmatic multicentre trial.. , 2012, , .		1
287	Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo).. Journal of Clinical Oncology, 2012, 30, 328-328.	0.8	0
288	Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC).. Journal of Clinical Oncology, 2012, 30, 6043-6043.	0.8	2

#	ARTICLE	IF	CITATIONS
289	Advances in Cancer Therapeutics and Patient Access to New Drugs. <i>Pharmacoeconomics</i> , 2011, 29, 213-224.	1.7	21
290	Biosimilars of Biological Drug Therapies. <i>Drugs</i> , 2011, 71, 1527-1536.	4.9	101
291	CCN3 Impairs Osteoblast and Stimulates Osteoclast Differentiation to Favor Breast Cancer Metastasis to Bone. <i>American Journal of Pathology</i> , 2011, 178, 2377-2388.	1.9	54
292	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	5.1	571
293	Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 296-304.	0.5	35
294	Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1377-1383.	2.9	31
295	Acquisition of metastatic tissue from patients with bone metastases from breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 761-765.	1.1	44
296	Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. <i>Supportive Care in Cancer</i> , 2011, 19, 315-322.	1.0	7
297	Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. <i>Supportive Care in Cancer</i> , 2011, 19, 1687-1696.	1.0	27
298	An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2011, 22, 1805-1811.	0.6	28
299	Breast Cancer Chemoprevention Gets Personal. <i>Journal of Clinical Oncology</i> , 2011, 29, 2296-2298.	0.8	3
300	Cost-effectiveness of Outpatient Management for Febrile Neutropenia in Children With Cancer. <i>Pediatrics</i> , 2011, 127, e279-e286.	1.0	53
301	Clinical Research: Show Us the Data. <i>Journal of Clinical Oncology</i> , 2011, 29, 1099-1100.	0.8	9
302	Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1299-1309.	3.0	538
303	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. <i>Journal of Clinical Oncology</i> , 2011, 29, 2543-2549.	0.8	64
304	Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions. <i>Journal of Clinical Oncology</i> , 2011, 29, 254-256.	0.8	80
305	The balance between benefits and harms of molecular targeted agents.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6030-6030.	0.8	1
306	A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 155-161.	1.1	14

#	ARTICLE	IF	CITATIONS
307	Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Research and Treatment, 2010, 122, 609-617.	1.1	39
308	Defining ovarian failure in amenorrheic young breast cancer patients. Breast, 2010, 19, 545-548.	0.9	17
309	A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D <sub>3</sub> in breast cancer patients with bone metastases. Cancer, 2010, 116, 284-291.	2.0	59
310	Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. Journal of the National Cancer Institute, 2010, 102, 680-691.	3.0	413
311	Absolute Benefits of Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer: Should We Know More?. Journal of Clinical Oncology, 2010, 28, e346-e347.	0.8	5
312	Do We Have to Change the Way Targeted Drugs Are Developed?. Journal of Clinical Oncology, 2010, 28, e420-e421.	0.8	12
313	Dose-dense treatment for triple-negative breast cancer. Nature Reviews Clinical Oncology, 2010, 7, 79-80.	12.5	24
314	Zoledronic acid for breast cancer therapy-induced bone loss. Nature Reviews Clinical Oncology, 2010, 7, 187-188.	12.5	10
315	Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews, 2010, 36, 410-415.	3.4	27
316	Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treatment Reviews, 2010, 36, 557-565.	3.4	51
317	Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.. Journal of Clinical Oncology, 2010, 28, 1007-1007.	0.8	22
318	Androgen deprivation therapy and bone loss. Nature Reviews Urology, 2009, 6, 642-644.	1.9	3
319	Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer. Journal of Clinical Pathology, 2009, 62, 474-476.	1.0	8
320	Antivascular agents for non-small-cell lung cancer: current status and future directions. Expert Opinion on Investigational Drugs, 2009, 18, 1667-1686.	1.9	7
321	Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?. Journal of Clinical Oncology, 2009, 27, 1919-1919.	0.8	2
322	Underestimation of Risk by Gail Model Extends Beyond Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2009, 27, 1526-1526.	0.8	4
323	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2009, 46, 811-817.	1.5	80
324	Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research and Treatment, 2009, 118, 377-383.	1.1	8

#	ARTICLE	IF	CITATIONS
325	Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 479-484.	1.7	18
326	Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 935-943.	1.7	27
327	Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 56-64.	2.0	3
328	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2009, 35, 685-691.	3.4	52
329	Biopsy confirmation of metastatic breast cancer: interim results of a prospective biopsy study. <i>Breast Cancer Research</i> , 2009, 11, .	2.2	3
330	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	1.9	223
331	Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. <i>Lancet Oncology</i> , The, 2009, 10, 933-935.	5.1	36
332	Amenorrhoea, menopause, and endocrine therapy for breast cancer. <i>BMJ: British Medical Journal</i> , 2009, 339, b4261-b4261.	2.4	10
333	Gene expression differences between disseminated tumor cells and tumor cells from overt bone metastases in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1040-1040.	0.8	0
334	Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer. <i>Anticancer Research</i> , 2009, 29, 2707-11.	0.5	10
335	Prevalence of Overt Metastases in Locally Advanced Breast Cancer. <i>Clinical Oncology</i> , 2008, 20, 340-344.	0.6	18
336	Discordance between Receptor Status in Primary and Metastatic Breast Cancer: an Exploratory Study of Bone and Bone Marrow Biopsies. <i>Clinical Oncology</i> , 2008, 20, 763-768.	0.6	57
337	Brostallicin hydrochloride. <i>Drugs of the Future</i> , 2008, 33, 0478.	0.0	0
338	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. <i>Journal of Medical Genetics</i> , 2004, 41, 474-480.	1.5	232
339	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. <i>Journal of Medical Genetics</i> , 2003, 40, 807-814.	1.5	261
340	Halitosis in children. <i>Journal of Pediatrics</i> , 1999, 134, 338-343.	0.9	53
341	Physiologic pigmentation of the oral mucosa in Israeli children. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1991, 71, 396-398.	0.6	39